Zaleplon improves sleep without producing rebound effects in outpatients with insomnia

International Clinical Psychopharmacology

Volumn 15, Issue 3, 2000, Pages 141-152

  Fry, June M ^a   Scharf, M ^b   Mangano, R ^c   Fujimori, M ^c   Berkowitz, D ^b   Bielksi, R ^d   Brown, D W ^e   Claghorn, J ^f   Doekel, R ^g   Duboff, E ^h   Erman, M K ⁱ   Lahmeyer, H ^j   Mendels, J ^k   Mendelson, W B ^l   Meredith, C ^m   Pascualy, R ⁿ   Rosenbaum, J ^o   Schumacher, D ^p   Ferguson, J ^q   Garland, W T ^aa   Imes, N ^r   Karacan, I ^s   Kreisle, J ^t   Sklar, B ^aa   Targum, S D ^u   Thien, S ^v   Vogel, G ^w   Walsh, J ^x   Wellman, J ^y   Wooten, V ^z   Blackman, Beatrice C ^aa   Burdette, Linda ^aa   Fritz, Theresa ^aa   McPherson, Mary Kay ^aa   Smith, D Joan ^aa   Whitaker, Timothy ^aa   Wickland, Carmen ^aa   more..

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Ctr for Research in Sleep Disorders   (United States)

^c WYETH AYERST RESEARCH   (United States)

^d Mood Disorders Institute   (United States)

^e Pharmco LSR Clinics   (United States)

^f Claghorn Lesem Research Clinic Inc   (United States)

^g Sleep Disorders Center of Alabama   (United States)

^h Center for Behavioural Medicine   (United States)

ⁱ SCRIPPS CLINIC   (United States)

^j Sleep Clinic   (United States)

^k Southern NJ Medical Center   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m Affiliated Research Institute   (United States)

ⁿ St John Providence Health System   (United States)

^o MASSACHUSETTS GENERAL HOSPITAL   (United States)

^p Hill Top Research Ltd   (United States)

^q Pharmacology Research Corporation   (United States)

^r Institute for Healthcare Research   (United States)

^s BAYLOR COLLEGE OF MEDICINE   (United States)

^t Center for Clinical Research   (United States)

^u CROZER CHESTER MEDICAL CENTER   (United States)

^v Pacific Research Network   (United States)

^w Sleep Research Laboratory   (United States)

^x ST LUKE S HOSPITAL   (United States)

^y InSite Clinical Trials Inc   (United States)

^z SENTARA NORFOLK GENERAL HOSPITAL   (United States)

^aa Sentara Norfolk General Hospital ^*

more..

Author keywords

Hypnotic; Insomnia; Rebound insomnia; Tolerance; Withdrawal; Zaleplon

Indexed keywords

ZALEPLON; ZOLPIDEM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REBOUND; SLEEP; VERTIGO; WITHDRAWAL SYNDROME;

EID: 0034079083     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015030-00003     Document Type: Article

References (24)

1. Allen D, Curran HV, Lader M (1993) The effects of single doses CL-284, 846, lorazepam, and placebo on psychomotor and memory function in normal male volunteers. Eur J Clin Pharmacol 45:313-320.
2. American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. Washington, DC: American Psychiatric Association.
3. Bartholini G (1988) Growing aspects of hypnotic drugs. In: Imidazopyridines in Sleep Disorders (Sauvanet JP, Langer SZ, Morselli PL, eds), New York: Raven Press. pp. 1-9.
4. Beer B, Ieni JR, Wu W-H, Clody D, Amorusi P, Rose J, et al. (1994) A placebo-controlled evaluation of single, escalating doses of CL 284, 846, a non-benzodiazepine hypnotic. J Clin Pharmacol 34:335-344.
5. A receptors different from zolpidem, zopiclone, and benzodiazepines. Neurosci Res Commun 25:139-148.
6. Élie R, Rüther E, Farr I, Emilien G, Salinas E (1999) Sleep latency is shortened during four weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry 60:536-544.
7. Fry J, Scharf MB, Berkowitz DV, Brown DW, Claghorn J, Ferguson J, et al. (1998) A phase III, 29 day, multicenter, randomized, double-blind comparator-and placebo-controlled, parallel-group safety, tolerability, and efficacy study of 5, 10 and 20 mg of zaleplon compared with 10 mg of zolpidem or placebo in adult outpatients with insomnia. Sleep 21 (Suppl.):262.
8. Hatoum HT, Kania, CM, Kong SX, Wong JM, Mendelson WB (1998) Prevalence of insomnia: a survey of the enrollees at five managed care organizations. Am J Manag Care 4:79-85.
9. Hobbs WR, Rall TW, Verdoorn TA (1996) Hypnotics and sedatives; ethanol. In: Goodman and Gilman's the Pharmacological Basis of Therapeutics (Hardman JA, Gilman AG, Limbird LE, eds), New York: McGraw Hill. p. 383.
10. Hohagen F, Rink K, Kappler C, Schramm E, Riemann D, Weyerer S, Berger M (1993) Prevalence and treatment of insomnia in general practice. Eur Arch Psychiatry Clin Neurosci 242:329-336.
11. Hurst M, Noble S (1999) Zaleplon. CNS Drugs 11:327-409.
12. Kryger MH, Steljes D, Pouliot Z, Neufeld H, Odynski T (1991) Subjective versus objective evaluation of hypnotic efficacy: experience with zolpidem. Sleep 14:399-407.
13. Kupfer DJ, Reynolds CF III (1997) Management of insomnia. New Engl J Med 336:341-346.
14. Langer SZ, Arbilla S, Scatton B, Niddam R, Dubois A (1988) Receptors involved in the mechanism of action of zolpidem. In: Imidazopyridines in Sleep Disorders (Sauvanet JP, Langer SZ, Morselli PL, eds), New York: Raven Press. pp. 55-70.
15. Maczaj M (1993) Pharmacological treatment of insomnia. Drugs 45:44-55.
16. Mendelson WB, Jain B (1995) An assessment of short-acting hypnotics. Drug Safety 13:257-270.
17. Salva P, Costa J (1995) Clinical pharmacokinetics and pharmacodynamics of zolpidem. therapeutic implications. Clin Pharmacokinet 29:142-153.
18. Scharf MB, Roth T, Vogel GW, Walsh JK (1994) A multicenter, placebo-controlled study evaluation of zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 55:192-199.
19. Stoller MK (1994) Economic effects of insomnia. Clin Therapeut 16:873-897.
20. Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, et al. (2000) Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance. J Clin Psychopharmacol (in press).
21. Tyrer P, Murphy S, Riley P (1990) The benzodiazepine withdrawal symptom questionnaire. J Affect Disord 19:53-61.
22. Vermeeren A, Danjou PE, O'Hanlon JF (1998) Residual effects of evening and middle-of-the-night administration of zaleplon 10 and 20 mg on memory and actual driving performance. Hum Psychopharmacol 13:S98-S107.
23. Vgontzas AN, Kales A, Bixler EO (1995) Benzodiazepine side effects: role of pharmacokinetics and pharmacodynamics. Pharmacology 51:205-223.
24. Walsh JK, Fry J, Erwin CW, Scharf M, Roth T, Vogel G (1998) Efficacy and tolerability of 14-day administration of zaleplon 5 mg and 10 mg for the treatment of primary insomnia. Clin Drug Invest 16:347-354.